| Autor: |
Vierboom, Michel P. M., Chenine, Agnes L., Darrah, Patricia A., Vervenne, Richard A. W., Boot, Charelle, Hofman, Sam O., Sombroek, Claudia C., Dijkman, Karin, Khayum, Mohamed A., Stammes, Marieke A., Haanstra, Krista G., Hoffmann, Chantal, Schmitt, Doris, Silvestre, Nathalie, White, Alexander G., Borish, H. Jacob, Seder, Robert A., Ouaked, Nadia, Leung-Theung-Long, Stephane, Inchauspé, Geneviève |
| Předmět: |
|
| Zdroj: |
NPJ Vaccines; 5/14/2020, Vol. 5 Issue 1, p1-12, 12p |
| Abstrakt: |
Tuberculosis (TB) still is the principal cause of death from infectious disease and improved vaccination strategies are required to reduce the disease burden and break TB transmission. Here, we investigated different routes of administration of vectored subunit vaccines based on chimpanzee-derived adenovirus serotype-3 (ChAd3) for homologous prime-boosting and modified vaccinia virus Ankara (MVA) for heterologous boosting with both vaccine vectors expressing the same antigens from Mycobacterium tuberculosis (Ag85B, ESAT6, Rv2626, Rv1733, RpfD). Prime-boost strategies were evaluated for immunogenicity and protective efficacy in highly susceptible rhesus macaques. A fully parenteral administration regimen was compared to exclusive respiratory mucosal administration, while parenteral ChAd3-5Ag prime-boosting and mucosal MVA-5Ag boosting were applied as a push-and-pull strategy from the periphery to the lung. Immune analyses corroborated compartmentalized responses induced by parenteral versus mucosal vaccination. Despite eliciting TB-specific immune responses, none of the investigational regimes conferred a protective effect by standard readouts of TB compared to non-vaccinated controls, while lack of protection by BCG underpinned the stringency of this non-human primate test modality. Yet, TB manifestation after full parenteral vaccination was significantly less compared to exclusive mucosal vaccination. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
